CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-12-18 | ASELAGE STEVE Chief Executive Officer | Grant or award | +20,625 | 272,148 | ||
| 2018-12-07 | ASELAGE STEVE Chief Executive Officer | Sale | −10 | $24.04 | $240 | 251,523 |
| 2018-11-29 | ASELAGE STEVE Chief Executive Officer | Gift | −1,750 | 251,533 | ||
| 2018-11-15 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,300 | $24.29 | $56K | 18,027 |
| 2018-11-15 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −100 | $24.77 | $2K | 17,927 |
| 2018-11-15 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −100 | $24.81 | $2K | 17,827 |
| 2018-11-15 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,188 | $24.25 | $53K | 18,304 |
| 2018-11-15 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −312 | $24.83 | $8K | 17,992 |
| 2018-11-15 | Clague Laura Chief Financial Officer | Sale | −2,959 | $24.20 | $72K | 12,824 |
| 2018-11-15 | Clague Laura Chief Financial Officer | Sale | −791 | $24.73 | $20K | 12,033 |
| 2018-11-15 | ASELAGE STEVE Chief Executive Officer | Sale | −4,464 | $24.21 | $108K | 254,369 |
| 2018-11-15 | ASELAGE STEVE Chief Executive Officer | Sale | −1,086 | $24.75 | $27K | 253,283 |
| 2018-11-14 | McFarlane Neil F. Chief Operating Officer | Sale | −9,000 | $23.63 | $213K | 29,476 |
| 2018-11-14 | McFarlane Neil F. Chief Operating Officer | Sale | −1,000 | $24.64 | $25K | 28,476 |
| 2018-11-14 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,200 | $23.62 | $52K | 20,627 |
| 2018-11-14 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −300 | $24.57 | $7K | 20,327 |
| 2018-11-14 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,200 | $23.62 | $52K | 20,792 |
| 2018-11-14 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −300 | $24.57 | $7K | 20,492 |
| 2018-11-14 | Clague Laura Chief Financial Officer | Sale | −3,350 | $23.63 | $79K | 16,183 |
| 2018-11-14 | Clague Laura Chief Financial Officer | Sale | −400 | $24.54 | $10K | 15,783 |
Page 49 of 51 · 1,020 trades